Tapan M Kadia

List of Publications by Year
in descending order

252 papers	13,343 citations	28190 55 h-index	32761 100 g-index
254 all docs	254 docs citations	254 times ranked	10096 citing authors

#	Article	IF	Citations
1	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, .	2.0	11
2	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood, 2022, 139, 907-921.	0.6	34
3	Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. American Journal of Hematology, 2022, 97, 68-78.	2.0	25
4	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2022, 97, E62.	2.0	17
5	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	2
6	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer Journal, 2022, 12, 10.	2.8	48
7	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12.	6.9	13
8	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Advances, 2022, 6, 3027-3035.	2.5	17
9	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer Journal, 2022, 12, 23.	2.8	4
10	Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337.	2.0	15
11	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer Journal, 2022, 12, 5.	2.8	49
12	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2022, 97, 574-582.	2.0	9
13	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American Journal of Hematology, 2022, 97, .	2.0	7
14	Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clinical Infectious Diseases, 2022, 75, 1503-1510.	2.9	16
15	Which FLT3 Inhibitor for Treatment of AML?. Current Treatment Options in Oncology, 2022, 23, 359-380.	1.3	5
16	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864.	2.0	33
17	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	2.0	12
18	TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72.	0.6	46

#	Article	IF	Citations
19	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	2.0	4
20	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	0.6	12
21	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer, 2022, 128, 2736-2745.	2.0	8
22	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology,the, 2022, 9, e350-e360.	2.2	26
23	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer Journal, 2022, 12, 77.	2.8	33
24	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances, 2022, 6, 4006-4014.	2.5	37
25	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1176-1184.	1.1	6
26	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	2.0	31
27	Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer Journal, 2022, 12, .	2.8	9
28	A dynamic 3â€factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	2.0	7
29	A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematologica, 2022, 145, 529-536.	0.7	14
30	Blinatumomab is associated with favorable outcomes in patients with Bâ€cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10^{â˜'4} and higher. American Journal of Hematology, 2022, 97, 1135-1141.	2.0	6
31	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857.	0.8	41
32	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clinical Infectious Diseases, 2021, 72, 1755-1763.	2.9	48
33	Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145.	0.7	57
34	The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia, 2021, 35, 691-700.	3.3	37
35	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	2.0	8
36	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatmentâ€related mortality. American Journal of Hematology, 2021, 96, 282-291.	2.0	59

#	Article	IF	Citations
37	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	2.6	50
38	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€ITD and IDH mutations. Cancer, 2021, 127, 381-390.	2.0	10
39	Phase 2 study of lenalidomide maintenance for patients with highâ€risk acute myeloid leukemia in remission. Cancer, 2021, 127, 1894-1900.	2.0	5
40	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1â€mutated acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1054-1063.	1.2	28
41	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 25.	2.8	85
42	Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal, 2021, 11, 41.	2.8	313
43	Decitabine and venetoclax for <scp>IDH1/2</scp>â€mutated acute myeloid leukemia. American Journal of Hematology, 2021, 96, E154-E157.	2.0	19
44	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer Journal, 2021, 11, 60.	2.8	22
45	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 2021, 127, 1186-1207.	2.0	74
46	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer Journal, 2021, 11, 52.	2.8	5
47	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 639387.	1.3	39
48	EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer Journal, 2021, 11, 64.	2.8	26
49	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	2.0	24
50	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) and myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>). American Journal of Hematology, 2021, 96, E246-E249.	2.0	9
51	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Advances, 2021, 5, 2156-2164.	2.5	33
52	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2021, 106, 2121-2130.	1.7	34
53	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer, 2021, 127, 2489-2499.	2.0	34
54	Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2184-2192.	0.6	10

#	Article	IF	Citations
55	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124.	2.0	5
56	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer, 2021, 127, 2648-2656.	2.0	33
57	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia treated with hyperâ€CVAD and dasatinib. Cancer, 2021, 127, 2641-2647.	2.0	15
58	An effective chemotherapyâ€free regimen of ponatinib plus venetoclax for relapsed/refractory <scp>P</scp>hiladelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2021, 96, E229-E232.	2.0	17
59	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances, 2021, 5, 1876-1883.	2.5	56
60	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499.	3.3	16
61	De novo acute myeloid leukemia: A populationâ€based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer, 2021, 127, 2049-2061.	2.0	79
62	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia, 2021, 35, 3282-3286.	3.3	61
63	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98.	2.8	24
64	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature Communications, 2021, 12, 2607.	5.8	61
65	<scp>FLT3</scp> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <scp>Acute Myeloid Leukemia</scp> with very low <scp>FLT3</scp> allelic burden. American Journal of Hematology, 2021, 96, E275-E279.	2.0	3
66	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. American Journal of Hematology, 2021, 96, 1000-1007.	2.0	23
67	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia, 2021, 35, 3421-3429.	3.3	22
68	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924.	2.0	13
69	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology, 2021, 11, 656218.	1.3	63
70	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood, 2021, 138, 1373-1377.	0.6	31
71	A phase 1b/2 study of azacitidine with PDâ€L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 3761-3771.	2.0	34
72	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Journal of Hematology and Oncology, 2021, 14, 94.	6.9	19

#	Article	IF	Citations
73	Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	2.0	40
74	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer, 2021, 127, 3552-3565.	2.0	19
75	Outcomes of TP53â€mutant acute myeloid leukemia with decitabine and venetoclax. Cancer, 2021, 127, 3772-3781.	2.0	80
76	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer, 2021, 127, 4421-4431.	2.0	4
77	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561.	2.2	81
78	Development of <scp>TP53</scp> mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	2.0	10
79	Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leukemia and Lymphoma, 2021, 62, 3402-3410.	0.6	12
80	Tenâ€day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity scoreâ€matched analysis. Cancer, 2021, 127, 4213-4220.	2.0	24
81	Novel Strategies in the Treatment of Older Patients with Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S51-S53.	0.2	0
82	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162.	2.8	32
83	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419.	2.5	24
84	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leukemia and Lymphoma, 2021, , 1-5.	0.6	2
85	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	0.8	173
86	First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leukemia and Lymphoma, 2020, 61, 445-449.	0.6	11
87	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	2.0	25
88	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	2.0	69
89	The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leukemia and Lymphoma, 2020, 61, 536-545.	0.6	8
90	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer, 2020, 126, 1152-1160.	2.0	29

#	Article	IF	Citations
91	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. Journal of Hematology and Oncology, 2020, 13, 132.	6.9	18
92	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	2.2	201
93	Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2775-2777.	0.6	4
94	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1288-1295.	2.0	28
95	Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. Expert Opinion on Emerging Drugs, 2020, 25, 491-499.	1.0	6
96	Phase 1 study of combinatorial sorafenib, <scp>Gâ€CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3â€ITD</scp>â€mutated acute myelogenous leukemia patients. American Journal of Hematology, 2020, 95, 1296-1303.	2.0	22
97	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533.	2.2	43
98	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	2.0	2
99	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Advances, 2020, 4, 6117-6126.	2.5	29
100	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689.	2.5	105
101	Impact of <scp>CD33</scp> and <scp>ABCB1</scp> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American Journal of Hematology, 2020, 95, E225-E228.	2.0	9
102	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e871-e882.	0.2	10
103	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia, 2020, 34, 2914-2924.	3.3	7
104	Identifying effective drug combinations for patients with acute myeloid leukemia. Expert Review of Anticancer Therapy, 2020, 20, 591-601.	1.1	4
105	The clinical impact of time to response in de novo acceleratedâ€phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1127-1134.	2.0	8
106	Phase 2 study of hyperâ€CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, 734-739.	2.0	10
107	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	3.3	37
108	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622.	2.0	51

#	Article	IF	Citations
109	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer, 2020, 126, 2193-2205.	2.0	33
110	Longâ€term results of frontline dasatinib in chronic myeloid leukemia. Cancer, 2020, 126, 1502-1511.	2.0	21
111	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discovery, 2020, 10, 506-525.	7.7	212
112	Clinical value of event-free survival in acute myeloid leukemia. Blood Advances, 2020, 4, 1690-1699.	2.5	4
113	Mechanistic basis and efficacy of targeting the Î²-cateninâ€“TCF7L2â€“JMJD6â€“c-Myc axis to overcome resistance to BET inhibitors. Blood, 2020, 135, 1255-1269.	0.6	27
114	Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2020, 21, 34.	1.3	2
115	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematologica, 2020, 143, 567-573.	0.7	53
116	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	2.5	86
117	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Advances, 2020, 4, 1311-1320.	2.5	106
118	Longâ€term results of a phase 2 trial of nilotinib 400Âmg twice daily in newly diagnosed patients with chronicâ€phase chronic myeloid leukemia. Cancer, 2020, 126, 1448-1459.	2.0	14
119	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood, 2020, 136, 18-20.	0.6	17
120	Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2020, 136, 11-12.	0.6	4
121	Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Blood, 2020, 136, 30-33.	0.6	3
122	Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2020, 136, 7-9.	0.6	5
123	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood, 2020, 136, 42-43.	0.6	11
124	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2020, 136, 17-19.	0.6	10
125	Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) Tj ETQq1 1 0.784314 rgBT	0.8	7
126	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539.	0.8	6

#	Article	IF	Citations
127	Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642.	0.8	77
128	Maintenance therapy in AML: The past, the present and the future. American Journal of Hematology, 2019, 94, 1254-1265.	2.0	56
129	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€“positive acute myeloid leukemia. Cancer, 2019, 125, 3755-3766.	2.0	38
130	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395.	2.0	26
131	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematology,the, 2019, 6, e480-e488.	2.2	103
132	Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection . Cancer Management and Research, 2019, Volume 11, 8817-8828.	0.9	23
133	Phase 1/2 study of DFPâ€10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer, 2019, 125, 1665-1673.	2.0	5
134	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer, 2019, 125, 3219-3224.	2.0	14
135	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 380, 2095-2103.	13.9	388
136	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	2.0	32
137	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 421-432.	1.8	31
138	Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586.	2.0	63
139	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood, 2019, 134, 59-73.	0.6	75
140	NPM1mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information inNPM1â€mutated acute myeloid leukemia. American Journal of Hematology, 2019, 94, E158-E160.	2.0	17
141	Clonal hematopoiesis of indeterminate potentialâ€“associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer, 2019, 125, 2233-2241.	2.0	19
142	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190.	2.0	4
143	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer, 2019, 125, 1855-1866.	2.0	21
144	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	2.5	84

#	Article	IF	Citations
145	Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. Future Oncology, 2019, 15, 3885-3894.	1.1	2
146	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84
147	Targeting nuclear Î²-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia, 2019, 33, 1373-1386.	3.3	32
148	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	7.7	380
149	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal, 2019, 9, 4.	2.8	57
150	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	6.9	257
151	Molecular pathogenesis of acquired aplastic anemia. European Journal of Haematology, 2019, 102, 103-110.	1.1	25
152	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3â€internal tandem duplication genotypes. Cancer, 2019, 125, 1091-1100.	2.0	50
153	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2647-2647.	0.6	11
154	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). Blood, 2019, 134, 290-290.	0.6	19
155	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	0.6	15
156	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. Blood, 2019, 134, 2582-2582.	0.6	2
157	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2640-2640.	0.6	12
158	Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, 7034-7034.	0.8	8
159	Treatment-free remission in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2019, 17, 686-696.	0.3	6
160	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer, 2018, 124, 2534-2540.	2.0	23
161	Final results of a phase 2, openâ€label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2018, 124, 2758-2765.	2.0	78
162	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248.	5.1	192

#	Article	IF	Citations
163	Outcomes with lower intensity therapy inTP53-mutated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2238-2241.	0.6	20
164	Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99.	2.0	74
165	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. American Journal of Hematology, 2018, 93, 84-90.	2.0	40
166	PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leukemia and Lymphoma, 2018, 59, 1486-1489.	0.6	3
167	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Miniâ€“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230.	3.4	124
168	Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 1012-1015.	0.6	3
169	Clinical experience with the <scp>BCL</scp>2â€inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology, 2018, 93, 401-407.	2.0	336
170	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 277-285.	2.0	54
171	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1788-1797.	0.8	156
172	Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer, 2018, 124, 4192-4201.	2.0	27
173	Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€hyperâ€CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first salvage. Cancer, 2018, 124, 4044-4055.	2.0	88
174	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline secondâ€and thirdâ€generation tyrosine kinase inhibitors. Cancer Medicine, 2018, 7, 5457-5469.	1.3	27
175	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia, 2018, 32, 2388-2398.	3.3	34
176	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. American Journal of Hematology, 2018, 93, E357-E360.	2.0	2
177	Prognosis of patients with intermediate risk IPSSâ€R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSSâ€R. American Journal of Hematology, 2018, 93, 1245-1253.	2.0	34
178	Sorafenib Combined with 5â€azacytidine in Older Patients with Untreated FLT3â€ITD Mutated Acute Myeloid Leukemia. American Journal of Hematology, 2018, 93, 1136-1141.	2.0	95
179	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia, 2018, 32, 2512-2518.	3.3	26
180	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapseâ€free survival. American Journal of Hematology, 2018, 93, 1376-1383.	2.0	17

#	Article	IF	Citations
181	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematology,the, 2018, 5, e411-e421.	2.2	66
182	Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia, 2018, 32, 2698-2701.	3.3	20
183	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 286-286.	0.6	19
184	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2018, 132, 36-36.	0.6	12
185	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood, 2018, 132, 34-34.	0.6	4
186	Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood, 2018, 132, 663-663.	0.6	7
187	Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.. Journal of Clinical Oncology, 2018, 36, 7014-7014.	0.8	36
188	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 845-850.	2.0	36
189	Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. Expert Review of Hematology, 2017, 10, 433-448.	1.0	30
190	Factors associated with risk of central nervous system relapse in patients with nonâ€core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 924-928.	2.0	17
191	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyperâ€CVADâ€based regimens. Cancer, 2017, 123, 3717-3724.	2.0	18
192	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 599-606.	2.0	38
193	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer, 2017, 123, 3050-3060.	2.0	47
194	Poor outcomes associated with +der(22)t(9;22) and â^'9/9p in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology, 2017, 92, 238-243.	2.0	41
195	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	0.6	214
196	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer, 2017, 123, 4851-4859.	2.0	45
197	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. American Journal of Hematology, 2017, 92, 1295-1302.	2.0	13
198	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439.	2.0	37

#	Article	IF	Citations
199	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	2.0	114
200	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <scp>B</scp>â€cell acute lymphoblastic leukemia. Cancer, 2017, 123, 294-302.	2.0	70
201	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia, 2017, 31, 678-687.	3.3	77
202	Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp>hiladelphia chromosomeâ€“negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	2.0	49
203	Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Review of Hematology, 2017, 10, 1-8.	1.0	47
204	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology, 2017, 92, 155-160.	2.0	30
205	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer, 2017, 123, 426-435.	2.0	63
206	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances, 2017, 1, 1312-1323.	2.5	83
207	Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Advances, 2017, 1, 1546-1550.	2.5	52
208	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2017, 18, 1618.	1.8	37
209	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2017, 130, 723-723.	0.6	35
210	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2017, 130, 815-815.	0.6	11
211	Alemtuzumab in T-cell large granular lymphocyte leukaemia. Lancet Haematology,the, 2016, 3, e4-e5.	2.2	2
212	Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood, 2016, 127, 1863-1869.	0.6	253
213	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood, 2016, 127, 1269-1275.	0.6	119
214	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discovery, 2016, 6, 1106-1117.	7.7	799
215	Hyperâ€CVAD plus ponatinib versus hyperâ€CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122, 3650-3656.	2.0	156
216	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	2.0	200

#	Article	IF	Citations
217	Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	1.2	102
218	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 163-168.e2.	0.2	18
219	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood, 2016, 128, 3171-3171.	0.6	2
220	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget, 2016, 7, 14172-14187.	0.8	86
221	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <scp>CD</scp>22 monoclonal antibody. American Journal of Hematology, 2015, 90, 193-196.	2.0	35
222	Phase I/II trial of the combination of midostaurin (PKC412) and 5â€azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 276-281.	2.0	139
223	Characteristics, clinical outcome, and prognostic significance of <scp>IDH</scp> mutations in <scp>AML</scp>. American Journal of Hematology, 2015, 90, 732-736.	2.0	242
224	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773.	2.0	27
225	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematology,the, 2015, 2, e12-e20.	2.2	24
226	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 653-661.	1.7	191
227	Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. American Journal of Hematology, 2015, 90, E139-41.	2.0	24
228	Toward Individualized Therapy in Acute Myeloid Leukemia. JAMA Oncology, 2015, 1, 820.	3.4	47
229	Final results of a phase 2 trial of clofarabine and lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer, 2015, 121, 2375-2382.	2.0	40
230	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555.	5.1	245
231	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.4	48
232	Progress in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 139-151.	0.2	40
233	Phase II study of methotrexate, vincristine, pegylatedâ€asparaginase, and dexamethasone (<scp>MO</scp>p<scp>AD</scp>) in patients with relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2015, 90, 120-124.	2.0	21
234	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2541-2541.	0.6	7

#	Article	IF	Citations
235	Impact of comorbidities by ACEâ€27 in the revisedâ€IPSS for patients with myelodysplastic syndromes. American Journal of Hematology, 2014, 89, 509-516.	2.0	30
236	Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 155-162.e1.	0.2	51
237	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAGâ€GO) as frontâ€line regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 2014, 89, 964-968.	2.0	62
238	Augmented Berlinâ€Frankfurtâ€MÃ¼nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer, 2014, 120, 3660-3668.	2.0	91
239	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients â‰60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2013, 88, 961-966.	2.0	46
240	Multiple recurrent extraâ€medullary relapses of highâ€grade diffuse large Bâ€cell lymphoma presenting in acute leukemic phase. American Journal of Hematology, 2013, 88, 433-434.	2.0	3
241	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662.	0.6	355
242	Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). Blood, 2013, 122, 5011-5011.	0.6	3
243	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Journal of Clinical Oncology, 2012, 30, 2204-2210.	0.8	158
244	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 244-251.	0.2	34
245	Impact of numerical variation in FMSâ€like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer, 2012, 118, 5819-5822.	2.0	17
246	Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer, 2012, 118, 5550-5559.	2.0	36
247	Final results of the phase <scp>II</scp> study of rabbit antiâ€thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colonyâ€stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. British Journal of Haematology, 2012, 157, 312-320.	1.2	36
248	Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.. Blood, 2012, 120, 2630-2630.	0.6	11
249	Failure of Hypomethylating Agentâ€“Based Therapy in Myelodysplastic Syndromes. Seminars in Oncology, 2011, 38, 682-692.	0.8	58
250	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 2010, 116, 4422-4429.	0.6	336
251	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. Journal of Clinical Oncology, 2010, 28, 392-397.	0.8	231
252	Role of epigenetic therapy in myelodysplastic syndrome. Expert Review of Hematology, 2008, 1, 161-174.	1.0	0